基于数据挖掘王成祥运用虫类药治疗肺系疾病规律研究

目的 分析王成祥教授临床运用虫类药治疗肺系疾病的配伍规律。方法 收集整理2019年11月—2021年11月王成祥教授含虫类药门诊处方401首,使用Microsoft Excel 2010和古今医案云平台（V2.3.5）构建数据库,利用频次分析、关联规则分析和复杂网络分析进行数据挖掘,结合验案举隅,探讨王成祥临证运用虫类药治疗肺系疾病的经验及特点。结果 研究共纳入医案257则,患者257例,401诊次,涉及呼吸系统疾病10种,阳性症状75种,舌质31种,舌苔42种,脉象26种,病机24条,药物184种,总用药频次6571次,其中,虫类药物4种,虫类药物总用药频次643次;王成祥教授常用虫类药按频次排序依次为蝉蜕、全蝎、僵蚕、地龙,常用剂量为6 g或10 g,不超过12 g;含虫类药的核心处方由蝉蜕、黄芩、苦杏仁、全蝎、半夏、五味子、甘草、干姜、枇杷叶9味药组成;临床表现前十位依次为咳嗽、白痰、咽痒、痰少或无、喘息、胸闷、气短、口干、黏痰、刺激性咳嗽;高频病机有痰热内蕴、寒饮停肺、风痰恋肺、痰瘀互结、气阴两虚、寒热错杂。结论 王成祥教授使用虫类药治疗肺系疾病时,精准选药,考究药量,注重肺的...     

夏秋季花粉症预防性治疗临床随机对照研究

目的 观察夏秋季花粉症临床症状特征,对比预防性治疗与非预防性治疗的临床疗效及生活质量差异。方法 采用随机对照临床试验,将确诊为花粉症且通过变应原皮肤点刺试验(skin prick test, SPT)以及血清特异性IgE(specific IgE,sIgE)检测明确为蒿属过敏患者随机分为预防组、对照组。花粉高峰期(8月15日至9月20日)前2周,预防组给予布地奈德鼻喷剂2次/d,连续2周,对照组未给予治疗;2周后两组均给予布地奈德鼻喷剂2次/d,依巴斯汀10 mg, 1次/d,孟鲁司特钠10 mg, 1次/d,连续治疗6周。每两周行花粉症症状(鼻部、眼耳咽部症状)评分、鼻结膜炎生活质量评分(RQLQ),记录不良反应。结果 共入组130例夏秋季花粉症患者,预防组65例、对照组65例,预防组第0、2、4、6周鼻部、眼耳咽部症状平均评分分别为9.32±3.00、5.31±2.80、3.68±2.80、1.54±2.20,低于对照组的症状评分10.17±3.60、5.85±3.80、4.55±3.90、2.86±3.00(F=5.406,P<0.05)。预防组自0周起每两周的RQLQ总体...     

Metformin can mitigate skeletal dysplasia caused by Pck2 deficiency

As an important enzyme for gluconeogenesis, mitochondrial phosphoenolpyruvate carboxykinase(PCK2) has further complex functions beyond regulation of glucose metabolism. Here, we report that conditional knockout of Pck2 in osteoblasts results in a pathological phenotype manifested as craniofacial malformation, long bone loss, and marrow adipocyte accumulation. Ablation of Pck2 alters the metabolic pathways of developing bone, particularly fatty acid metabolism. However, metformin treatment can mi...     

综合疗法治疗脑梗死的临床研究

目的：探讨综合疗法治疗脑梗死的临床疗效。方法：脑梗死患者80例,随机分为综合组和药物组各40例,均按常规药物治疗,综合组同时氦-氖激光血管体表照射、超声波及针刺治疗。结果：治疗30 d后,总有效率比较综合组明显高于药物组（95.7%、80%,P〈0.05）;综合组血流量、血脂和血液流变学指标的改善均明显优于治疗前及药物组（均P〈0.05）。结论：综合疗法能显著改善脑梗死患者的血流速度、血脂和血液流变学指标,提高康复效果。     

浅谈BOPPPS教学模式在病理学线上教学中的运用

疫情特殊情况下,我们将BOPPPS教学模式中"目标、前测、参与、后测、总结"等元素融入到病理学线上教学中,紧紧围绕教学目标开展"课前网络自学+课堂参与式在线直播+课后在线作业讨论"的线上学习模式:借助网络资源和电子教材锻炼并促进学生的自主学习能力;通过参与式直播为学生答疑解惑,帮助学生掌握和理解病理学重点与难点;通过在...     

Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy

Gemcitabine has been extensively applied in treating various solid tumors. Nonetheless,the clinical performance of gemcitabine is severely restricted by its unsatisfactory pharmacokinetic parameters and easy deactivation mainly because of its rapid deamination, deficiencies in deoxycytidine kinase (DCK), and alterations in nucleoside transporter. On this account, repeated injections with a high concentration of gemcitabine are adopted, leading to severe systemic toxicity to healthy cells. Accord...     

Metal ions-bridged J-aggregation mediated nanoassembly composition for breast cancer phototherapy

Recently, the highly ordered J-aggregates of organic dyes with intriguing optical properties have received considerable attention in biomedical applications. Herein, binary metal ions Mn(Ⅱ)/Fe(Ⅲ) are used to induce the formation of indocyanine green(ICG) J-aggregates.Further, the sheet-like J-aggregates are able to act as "carriers" for loading hydrophobic chemotherapeutic gambogic acid(GA), realizing the effect of "killing two birds with one stone" for both treatment and delivery. The as-design...     

难治性鼻出血治疗的探讨

本文难治性鼻出血定义为鼻出血呈发作性,前鼻镜检查未发现可疑出血灶,规范鼻腔填塞无效,或填塞后血止,撤出填塞物再出血。由于出血部位深而隐蔽,常规治疗效果差,对鼻腔正常黏膜损伤大,填塞导致的鼻、头部疼痛常令许多患者难以忍受。本文对我院2005-11-01--2007-11-01诊治的74例难治性鼻出血患者的临床资料进行回顾性分析。     

超声造影实时动态观察特殊部位肝癌微波消融联合聚桂醇治疗的应用价值

目的探讨超声造影实时动态观察下特殊位置肝癌微波消融与聚桂醇联合治疗的应用价值。方法采用回顾性研究方法,选取2017年4月至2018年3月空军军医大学第一附属医院住院治疗的原发性肝癌患者120例,按照治疗方案不同将患者平均分为两组:观察组60例患者选择超声造影引导微波消融联合聚桂醇治疗,对照组60例患者选择超声造影引导微波消融治疗。对比两组患者的临床治疗效果以及并发症情况。结果观察组与对照组患者肿瘤灶数分别为92个、94个,穿刺数分别为174个、181个,消融位数分别为351个、357个,观察组肿瘤灶完全灭活率(超声造影:93. 48%;增强CT:89. 13%)明显高于对照组(超声造影:72. 34%;增强CT:69. 15%),差异具有统计学意义(P 0. 05),超声造影与增强CT检查肿瘤灶完全灭活率差异无统计学意义(P 0. 05)。观察组患者并发症发生率为61. 67%,对照组为73. 33%,两组相比差异无统计学意义(P 0. 05)。结论超声造影实时动态观察下微波消融结合聚桂醇注射治疗特殊位置的原发性肝癌有良好的临床效果,肿瘤病灶的灭活率较高而并发症较少,超声造影实时观察肝癌病灶情况较为准确,对特殊位置肝癌治疗的临床价值较高。     

Prevention of intrauterine infection by hepatitis B virus with hepatitis B immune globulin: efficacy and mechanism

Objective　To evaluate the efficacy of hepatitis B immune globulin (HBIG) in preventing intrauterine infection by hepatitis B virus (HBV) and to investigate its mechanism. Methods　Forty-eight pregnant women positive for hepatitis B surface antigen (HBsAg) were randomly divided into 2 groups. The 34 women in the study group were injected with HBIG during pregnancy; the other 14 women were controls. Maternal blood samples were taken before HBIG injection and at delivery. Neonatal blood samples were taken within 24 hours after birth before HBIG and hepatitis B vaccine were given. HBsAg and antibody to HBsAg (anti-HBs) were tested by radioimmunoassay. Results　None of the 35 newborns (including 2 twins) in the study group was positive for HBsAg, but 3 (21%) in the control group were positive (P=0.02). The HBsAg titers in the women in the study group decreased after HBIG injection. Of the 35 newborns in the study group, 32 (91%) were positive for anti-HBs. Conclusion　Systematic injections of HBIG during pregnancy may prevent intrauterine HBV infection, the mechanism of which may be reduction of maternal HBV viremia and production of fetal passive immunity.